替吉奥联合腹腔化疗方案治疗胃癌腹水的临床效果观察  

Observation on clinical efficacy of tegafur gimeracil oteracil potassium vein combined with intraperitoneal chemotherapy treatment gastric cancer ascites

作　　者：尚红娟 黄龙璋 邓泽锋 王帆 何秀琴 万保林 

机构地区：[1]江西省九江市第三人民医院肿瘤科,江西九江332000

出　　处：《中国当代医药》2014年第25期99-101,共3页China Modern Medicine

摘　　要：目的：探讨替吉奥联合腹腔化疗方案治疗胃癌腹水的临床效果。方法选取2012年3月~2013年11月到本院接受治疗的胃癌并发腹水患者64例，随机分为对照组与观察组，每组各32例，对照组患者给予常规治疗，观察组采用替吉奥联合腹腔化疗方案治疗，分析对比两组患者的治疗效果。结果与对照组比较，观察组患者的腹水量明显较少，两组差异有统计学意义（P〈0.05）。对照组患者的治疗有效率为62.5%，观察组为87.5%，两组差异有统计学意义（P〈0.05）。结论替吉奥联合腹腔化疗方案治疗胃癌并发腹水的临床效果较好，值得进一步推广使用。Objective To explore the clinical effect of tegafur gimeracil oteracil potassium combined with intraperi-toneal chemotherapy treatment gastric cancer ascites. Methods 64 cases with gastric cancer ascites treated in our hos-pital from March 2012 to November 2013 were selected and randomly divided into control group and the observation group,each group of 32 cases.The control group received conventional treatment,and the observation group received tegafur gimeracil oteracil potassium combined with intraperitoneal chemotherapy.The treatment effect of two groups was compared and analyzed. Results Compared with the control group,the ascites volume in the observation group was low-er,which had statistical significance （P〈0.05）.The effective rate in the control group was 62.5%,and that of the observa-tion group was 87.5%,which had statistical significance （P〈0.05）. Conclusion Tegafur gimeracil oteracil potassium combined with intraperitoneal chemotherapy treating patients with gastric cancer ascites has good clinical effect,which is worthy of promotion and application.

关 键 词：替吉奥 静脉联合腹腔化疗 胃癌腹水 

分 类 号：R735.2[医药卫生—肿瘤]